BTEC:LSE:LSE-iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) (USD)

ETF | Others |

Last Closing

USD 6.435

Change

-0.01 (-0.18)%

Market Cap

USD 0.48B

Volume

2.92K

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-24 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
XNID:LSE Xtrackers Nifty 50 Swap UCITS ..

N/A

USD 292,109.69B
XMTD:LSE Xtrackers MSCI Taiwan UCITS ET..

N/A

USD 292,109.19B
0R1O:LSE Amazon.com Inc.

N/A

USD 1,607.29B
0R1I:LSE NVIDIA Corp.

N/A

USD 618.20B
LCJD:LSE Amundi MSCI Japan (DR) UCITS E..

N/A

USD 553.83B
LCJP:LSE Lyxor Core MSCI Japan (DR) UCI..

N/A

USD 553.83B
0R1G:LSE Home Depot Inc.

N/A

USD 373.16B
XDJP:LSE Xtrackers Nikkei 225 UCITS ETF..

N/A

USD 331.07B
0QZK:LSE Coca-Cola Co.

N/A

USD 266.08B
0QZO:LSE 0QZO

N/A

USD 258.54B

ETFs Containing BTEC:LSE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 0.86% 35% F 40% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 0.86% 34% F 39% F
Trailing 12 Months  
Capital Gain 9.60% 46% F 53% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 9.60% 45% F 52% F
Trailing 5 Years  
Capital Gain 38.24% 56% F 65% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 38.24% 53% F 63% D
Average Annual (5 Year Horizon)  
Capital Gain 6.56% 59% D- 64% D
Dividend Return 6.56% 58% F 63% D
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 19.66% 36% F 51% F
Risk Adjusted Return 33.39% 54% F 67% D+
Market Capitalization 0.48B 69% C- 59% D-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.